Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer.
Papadimitriou MC, Pazaiti A, Iliakopoulos K, Markouli M, Michalaki V, Papadimitriou CA. Papadimitriou MC, et al. Among authors: michalaki v. Biochim Biophys Acta Mol Cell Res. 2022 Dec;1869(12):119346. doi: 10.1016/j.bbamcr.2022.119346. Epub 2022 Aug 24. Biochim Biophys Acta Mol Cell Res. 2022. PMID: 36030016 Free article. Review.
Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" study).
Alexopoulos A, Karanikiotis C, Ardavanis A, Boukovinas I, Makrantonakis P, Papadimitriou C, Athanasiadis A, Boutis A, Giassas S, Kakolyris S, Koumakis G, Papazisis K, Psyrri A, Ziras N, Baka S, Kentepozidis N, Michalaki V. Alexopoulos A, et al. Among authors: michalaki v. Anticancer Res. 2022 Feb;42(2):1031-1041. doi: 10.21873/anticanres.15564. Anticancer Res. 2022. PMID: 35093904
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D, Tsavaris N. Gennatas C, et al. Among authors: michalaki v. Tumori. 2006 Jan-Feb;92(1):13-7. doi: 10.1177/030089160609200103. Tumori. 2006. PMID: 16683378 Clinical Trial.
Genetic Predisposition to Male Breast Cancer: A Case Series.
Apessos A, Agiannitopoulos K, Pepe G, Tsaousis GN, Pitta P, Bili C, Florentin L, Saloustros E, Kampletsas E, Tryfonopoulos D, Tsoukalas N, Bournakis E, Zagouri F, Kotsakis A, Koumarianou A, Korantzis I, Boukovinas I, Lypas G, Fountzilas G, Michalaki V, Xynogalos S, Linardou H, Papadopoulou E, Nasioulas G, Georgoulias V. Apessos A, et al. Among authors: michalaki v. Anticancer Res. 2022 Dec;42(12):5795-5801. doi: 10.21873/anticanres.16086. Anticancer Res. 2022. PMID: 36456130
36 results